Ukusebenzisa utshwala kungathinta ukwelashwa kwakho ngezindlela eziningi.
Umsebenzi we-Bone Marrow
Umphumela wokuqala nokumangalisa ukuthi udoti ungaba nawo maqondana nendlela umthambo wakho osebenza ngayo. Utshwala lungaphazamisa ukukhiqizwa okunempilo kwamangqamuzana egazi amhlophe, amangqamuzana egazi abomvu, namaplatelets emangeni lakho. Ukuze iziguli ezinegazi nekhanda lomdlavuza we-marrow, njenge- leukemia , i-lymphoma, ne- myeloma , umsebenzi we-bone lomnkantsha kungenzeka usuvele unzima ngenxa yesifo sabo.
Uma wengeza lokho emonakalweni womnkantsha wamathambo okwenzeka ngenxa ye-chemotherapy kanye nokwelapha imishanguzo, umthelela ungase ube mkhulu kakhulu nakakhulu nakakhulu.
Imiphumela Yomdlandla
Utshwala, njengoba cishe usuvele uwazi ngokuhlangenwe nakho, kuyisidakamizwa. Kuyasiza ukuphumula umzimba wakho futhi kunomthelela wokubuthongela ukulala kwakho. Kodwa-ke, njengomphumela womdlavuza wakho, kungenzeka usuvele ulwa nokukhathala njalo, futhi utshwala lungenza inkinga ibe yimbi nakakhulu. Uma uthatha noma yimiphi imithi yokusiza ukulawula ubuhlungu bakho noma isicanucanu , utshwala luzokwengeza emiphumeleni yokudambisa yalowo mithi. Ukuze usebenze futhi ujabulele izinga lakho lokuphila, ukunciphisa noma ukuqeda udoti kungase kube umqondo.
Ukuthukuthela kwesisu sakho
Uma uke wabhekana nesicanucanu njengomphumela ohlangothini oluvela emithini yokwelashwa noma i-chemotherapy, kufanele wazi nokuthi utshwala bubangela uhlobo olufanayo lokucasula emgodini wesisu nesisu sakho njengalezo zokwelapha.
Lokhu kuhlanganisa neziguli ezitholakala ngomlomo we-mucositis noma izilonda zomlomo. Ukuphuza utshwala kungalimaza kakhulu lo mphumela ohlangothini olukhulu.
Ukucindezela esiqhingini
Imithi eminingi ye-chemotherapy idonswa emzimbeni wakho ngesibindi sakho. Imiphumela emibi yalezi zidakamizwa ingabeka ukuqina kwangempela esibindi. Utshwala uphinde luboniswe ngesibindi sakho futhi uphuze kuyomane udale ukucindezeleka okungeziwe futhi mhlawumbe umonakalo unomphela kuleso sitho.
Ingabe Kudingeka Ugweme Utshwala Ngokuphelele?
Ngakho udinga ukugwema utshwala ngokuphelele? Udokotela wakho noma umhlinzeki wezokunakekelwa kwezempilo ngumuntu ongcono kakhulu wokukwazisa ngale ndaba. Ama-cancer ehlukile egazi angase abe nezifundo ezahluke kakhulu. Amanye ama-leukemia angapheli kanye nama-lymphomas angeke adinge ukwelashwa ekuqaleni, isibonelo, futhi umthwalo ngokushintsha izinguquko zokuphila okunconywayo kungenzeka ukuthi awubalulekile kakhulu. Ngokuyinhloko, kunconywa ukuthi ugweme ukuphuza ngenkathi uthola ukwelashwa. Uma lokhu kungamukeleki neze kuwe, ukusebenzisa amanani amancane ekumodeni kungavunyelwa ochwepheshe bakho.
Kubalulekile ukuthi uma ukhuluma ngokusetshenziswa kotshwala nethimba lakho lokunakekelwa kwezempilo, uphambili futhi uthembekile ngobungako obuthathayo. Uma uphuza njalo, ithimba lakho kufanele lazi ukuthi ngakho lingakusiza ukusika kancane kancane kancane kancane. Ukuyeka ukuphuza utshwala kungabangela imiphumela embi yokwelapha.
I-American Cancer Society inikeza lesi sitatimende ngokuphuza utshwala ngesikhathi se-chemotherapy yomdlavuza:
Njengemibuzo eminingi ehlobene nokuphathwa kokwelashwa komuntu othile, kungcono ukuthi isiguli sihlole ithimba labo lokunakekelwa kwezempilo ngokuthi ngabe cha noma liphephile yini ukuphuza utshwala ngesikhathi noma ngokulandela ukwelashwa kwamakhemikhali. Odokotela nabahlengikazi abaphatha ukwelashwa bazokwazi ukunikeza iseluleko esithile mayelana nokuthi ukuphuza utshwala kuphephile ngamakhemikhali athile we-chemotherapy kanye / noma eminye imithi enqunywe kanye ne-chemotherapy.
Ingabe Utshwala Awunayo Izinzuzo Zempilo?
Ucwaningo oluningi luye lwasikisela ukuthi izinzuzo zezempilo zingase zihlotshaniswe nokuphuza ngokulinganisa. Ngokuyinhloko, iwayini elibomvu liye labizwa kabanzi ngokuthi libe nezinzuzo ezithile zezempilo ezisekelwe ekuhlolisweni kwelabhorethri okubonisa ukuthi izinto ezidini elibomvu zingaba nezindawo zokulwa nomdlavuza. I-Resveratrol yinto eyodwa enjalo, engatholakala kumagilebhisi, ama-raspberries, amantongomane, nokunye okunye okudla okutshalwe yizitshalo. Nokho, ngokusho kwe-American Cancer Society, izilingo zempilo kubantu azizange zinikeze ubufakazi bokuthi i-resveratrol iphumelela ekuvikeleni noma ekwelapheni umdlavuza.
Abanye abalobi baye baphakamisa ukuthi utshwala bobabili i-tonic kanye nobuthi. Uma abaphuza bezolinganisa kuphela isiphuzo esisodwa, hhayi njalo nsuku zonke, kungenzeka ukuthi izinzuzo zezempilo zingase zibe kakhulu. Izifundo eziningi ezizokwenza zibonise ukuthi ngokuphuza okulinganiselwe , kunengozi encane yokuhlaselwa yinhliziyo, ischemic (i-clot-caused cause), isifo se-peripheral vascular, ukufa okuphazamiseka kwenhliziyo, nokufa kuzo zonke izimbangela ze-cardiovascular. Kulinganiselwa ukuthi abangaba yizigidi ezingama-18.2 baseMelika bahlangabezana nemigomo ejwayelekile yokusebenzisa kabi utshwala noma ukuphuza utshwala, noma kunjalo; futhi, iziphuzo eziningi azikwazi ukuzikhawulela ukuhlangabezana nezidingo zokufunda zokuphuza okulinganiselwe. Ngaphezu kwalokho, izinzuzo zenhliziyo nesistimu yemisipha yegazi zingabhekana nezinkinga zokudla.
Izwi elivela
Utshwala luvame ukuyingxenye yomphakathi kanye namasiko emazingeni amaningi ahlukene kangangokuthi kungase kungabi lula njengokuzwakalayo ukuyeka izizathu zezempilo ngemuva kokuhlonza umdlavuza. Lokho kusho ukuthi kunabantu abathile abangeke baphuze utshwala kanye nezimo ezithile zomtholampilo lapho ukuphuza utshwala kungakhanjelwa khona. Ngesikhathi ukwelashwa, utshwala lungaba nomthelela ekwelapheni kwakho ngokufaka emiphumeleni emibi nakakhulu. Xoxa nokusebenzisa kwakho utshwala nodokotela wakho noma ithimba lezokunakekela impilo ukuze uthole ukuthi iyiphi imali, uma ikhona, iyamukeleka ohlelweni lwakho lwezokwelapha.
> Imithombo:
> Druesne-Pecollo N, Tehard B, uMallet Y, et al. Utshwala kanye nama-polymorphisms ezakhiweni: kubangelwa ingozi yomdlavuza ohlobene nophuzo. I-Lancet Oncology 2009; 10 (2): 173-180
> Tramacere I, Pelucchi C, Bonifazi M, et al. Ukuhlaziywa kwe-meta ekuphuzeni utshwala kanye nengozi ye-Hodgkin lymphoma. I-European Journal of Cancer Prevention 2012; 21 (3): 268-273.